(S)-(+)-Ibuprofen

(S)-(+)-Ibuprofen

• CAS Number: 51146-56-6
• UNSPSC Description: (S)-(+)-Ibuprofen ((S)-Ibuprofen), a S(+)-enantiomer of Ibuprofen, is a potent COX-1 and COX-2 inhibitor with IC50s of 2.1 μM and 1.6 μM, respectively. (S)-(+)-Ibuprofen has analgesic, anti-inflammatory, anticancer and antipyretic effects[1][2].
• Target Antigen: COX
• Type: Reference compound
• Related Pathways: Immunology/Inflammation
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology; Cancer
• Assay Protocol: https://www.medchemexpress.com/_S_-__addition__-Ibuprofen.html
• Purity: 99.99
• Solubility: DMSO : 100 mg/mL (ultrasonic)|Ethanol : 100 mg/mL (ultrasonic)|H2O : 1 mg/mL (ultrasonic;warming)
• Smiles: OC([C@H](C1=CC=C(CC(C)C)C=C1)C)=O
• Molecular Weight: 206.28
• References & Citations: [1]Evans AM, et al. Comparative pharmacology of S(+)-ibuprofen and (RS)-ibuprofen. Clin Rheumatol. 2001 Nov;20 Suppl 1:S9-14.|[2]N Scheuren, et al. Modulation of transcription factor NF-kappaB by enantiomers of the nonsteroidal drug ibuprofen. Br J Pharmacol. 1998 Feb;123(4):645-52.|[3]Astrid Janssen, et al. Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment. Eur J Pharmacol. 2006 Jul 1;540(1-3):24-33.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Launched